Steroid versus placebo for sudden worsening of lung scarring
Part of Lungs & breathing clinical trials.
This Phase 3 trial studies whether glucocorticoid (steroid) medicine helps people with idiopathic pulmonary fibrosis (IPF) who have a sudden flare-up, compared with an inactive placebo. You may be helped if steroids improve breathing and recovery during these acute episodes, but the study is designed to test that clearly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have IPF (or doctors strongly suspect IPF)
- You recently had an acute flare-up with new breathing worsening within about 1 month, and scans show new lung changes (or—if scan is missing—your team may still call it “suspected flare-up”)
- Your flare-up is not fully explained by heart failure or fluid overload, and no other clear cause (like a specific infection) has been found
- If you can become pregnant, you agree to effective birth control during the study
- You can sign consent (or a legally approved relative can sign for you)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a medication called intravenous immunoglobulin (IVIG) can help people with IPF who are hospitalized for a sudden worsening of their lung condition. The treatment aims to reduce inflammation and improve recovery.
This study looks at whether simple blood tests done when you are admitted to the hospital for a sudden worsening of pulmonary fibrosis (called an acute exacerbation) can help predict how you will do. This might help doctors plan better care.
This trial tests whether taking a corticosteroid (a type of anti-inflammatory medicine) for six months can help people with fibrotic hypersensitivity pneumonitis, a lung disease that causes scarring and makes it hard to breathe. The study compares the drug to a placebo (a pill with no active medicine) to see if it improves lung function or slows down the disease.
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
This trial tests whether a new treatment made from menstrual blood stem cells, given by injection, can help people with IPF, a condition that causes lung scarring and makes breathing harder. The study aims to see if the treatment can slow down the disease and improve lung function.
This study tests whether a new drug called nerandomilast can slow down scarring in the lungs for people with certain types of fibrosing interstitial lung disease (a condition where lung tissue becomes thick and scarred). You may qualify if you have lung scarring that is getting worse and haven't tried this or similar drugs before.
Hear when a new Acute Exacerbation of Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.